Your browser doesn't support javascript.
loading
The 2012 Briganti nomogram not only predicts lymph node involvement but also disease progression in surgically treated intermediate-risk prostate cancer patients with PSA <10 ng/mL, ISUP grade group 3, and clinical stage up to cT2b.
Porcaro, Antonio Benito; Panunzio, Andrea; Orlando, Rossella; Montanaro, Francesca; Baielli, Alberto; Artoni, Francesco; Gallina, Sebastian; Bianchi, Alberto; Mazzucato, Giovanni; Serafin, Emanuele; Patuzzo, Giulia Marafioti; Veccia, Alessandro; Rizzetto, Riccardo; Brunelli, Matteo; Migliorini, Filippo; Bertolo, Riccardo; Tafuri, Alessandro; Cerruto, Maria Angela; Antonelli, Alessandro.
Afiliação
  • Porcaro AB; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Panunzio A; Department of Urology, Vito Fazzi Hospital, Lecce, Italy.
  • Orlando R; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Montanaro F; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Baielli A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Artoni F; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Gallina S; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Bianchi A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Mazzucato G; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Serafin E; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Patuzzo GM; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Veccia A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Rizzetto R; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Brunelli M; Department of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Migliorini F; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Bertolo R; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Tafuri A; Department of Urology, Vito Fazzi Hospital, Lecce, Italy.
  • Cerruto MA; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Antonelli A; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Int Braz J Urol ; 50(4): 450-458, 2024.
Article em En | MEDLINE | ID: mdl-38743063
ABSTRACT

PURPOSE:

We assessed the prognostic impact of the 2012 Briganti nomogram on prostate cancer (PCa) progression in intermediate-risk (IR) patients presenting with PSA <10ng/mL, ISUP grade group 3, and clinical stage up to cT2b treated with robot assisted radical prostatectomy eventually associated with extended pelvic lymph node dissection. MATERIALS AND

METHODS:

From January 2013 to December 2021, data of surgically treated IR PCa patients were retrospectively evaluated. Only patients presenting with the above-mentioned features were considered. The 2012 Briganti nomogram was assessed either as a continuous and a categorical variable (up to the median, which was detected as 6%, vs. above the median). The association with PCa progression, defined as biochemical recurrence, and/or metastatic progression, was evaluated by Cox proportional hazard regression models.

RESULTS:

Overall, 147 patients were included. Compared to subjects with a nomogram score up to 6%, those presenting with a score above 6% were more likely to be younger, had larger/palpable tumors, presented with higher PSA, underwent tumor upgrading, harbored non-organ confined disease, and had positive surgical margins at final pathology. PCa progression, which occurred in 32 (21.7%) cases, was independently predicted by the 2012 Briganti nomogram both considered as a continuous (Hazard Ratio [HR]1.04, 95% Confidence Interval [CI]1.01-1.08;p=0.021), and a categorical variable (HR2.32; 95%CI1.11-4.87;p=0.026), even after adjustment for tumor upgrading.

CONCLUSIONS:

In IR PCa patients with PSA <10ng/mL, ISUP grade group 3, and clinical stage up to cT2b, the 2012 Briganti nomogram independently predicts PCa progression. In this challenging subset of patients, this tool can identify prognostic subgroups, independently by upgrading issues.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prostatectomia / Neoplasias da Próstata / Antígeno Prostático Específico / Progressão da Doença / Nomogramas / Gradação de Tumores / Estadiamento de Neoplasias Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Int Braz J Urol Assunto da revista: UROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prostatectomia / Neoplasias da Próstata / Antígeno Prostático Específico / Progressão da Doença / Nomogramas / Gradação de Tumores / Estadiamento de Neoplasias Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Int Braz J Urol Assunto da revista: UROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália País de publicação: Brasil